Skip to main content
. 2018 Sep 17;10:3589–3597. doi: 10.2147/CMAR.S172261

Figure 3.

Figure 3

Kaplan–Meier curve analyses of OS. (A) In the low PC group, patients who received bevacizumab had better OS. (B) In the high PC group, there was no significant difference in OS in terms of bevacizumab treatment.

Abbreviations: OS; overall survival; PC, perivascular cell coverage.